Your browser doesn't support javascript.
loading
TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff, Elizabeth; Sato, Yosuke; Mai, Doanh; Appleman, Vicky A; Iwasaki, Shinji; Kolev, Vihren; Matsuda, Atsushi; Shi, Judy; Mochizuki, Michiyo; Yoshikawa, Masato; Huang, Jian; Shen, Luhua; Haridas, Satyajeet; Shinde, Vaishali; Gemski, Chris; Roberts, Emily R; Ghasemi, Omid; Bazzazi, Hojjat; Menon, Saurabh; Traore, Tary; Shi, Pu; Thelen, Tennille D; Conlon, Joseph; Abu-Yousif, Adnan O; Arendt, Christopher; Shaw, Michael H; Okaniwa, Masanori.
Afiliação
  • Carideo Cunniff E; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Sato Y; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Mai D; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Appleman VA; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Iwasaki S; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan.
  • Kolev V; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Matsuda A; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan.
  • Shi J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Mochizuki M; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan.
  • Yoshikawa M; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan.
  • Huang J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Shen L; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Haridas S; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Shinde V; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Gemski C; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Roberts ER; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Ghasemi O; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Bazzazi H; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Menon S; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Traore T; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Shi P; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Thelen TD; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Conlon J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Abu-Yousif AO; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Arendt C; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Shaw MH; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
  • Okaniwa M; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.
Cancer Res Commun ; 2(6): 489-502, 2022 06.
Article em En | MEDLINE | ID: mdl-36923556
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunidade Inata / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunidade Inata / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article